快速脑MRI与常规临床MRI在3级和4级胶质瘤患者中的诊断效能比较:一项初步研究
这项回顾性初步研究纳入35例3级和4级胶质瘤患者共93次MRI检查(58次随访),由3名读者按RANO 2.0标准评估EPIMix快速脑MRI与常规临床MRI对肿瘤分类和进展期病变的诊断效能。EPIMix与常规MRI的肿瘤分类一致性接近完美(κ=0.96和0.89),检测进展期病变的敏感度为1.00和0.90、特异度均为0.97、AUC为0.99和0.94。作者认为EPIMix可作为3级和4级胶质瘤治疗评估的快速MRI替代方案,诊断效能高但略低于常规临床MRI。
要点
- EPIMix与常规临床MRI的肿瘤分类一致性接近完美(κ=0.96和0.89)。
- EPIMix检测进展期病变敏感度为1.00(R1)和0.90(R2),特异度均为0.97。
- EPIMix诊断效能高但略低于常规临床MRI,作者将其作为快速替代方案。
核心结论
- 在这项初步研究中,EPIMix被用作3级和4级胶质瘤患者治疗评估的快速MRI替代方案,诊断效能高但略低于常规临床MRI。
研究设计与样本
- 回顾性纳入35例经常规临床MRI和EPIMix检查的3级和4级胶质瘤患者,共93次MRI检查、58次随访。3名读者参与评估,其中R1和R2独立评估EPIMix后评估常规临床MRI,按RANO 2.0标准测量增强和非增强肿瘤区域。评估不一致的病例由R3参与进行非盲法并排阅读。以常规临床MRI为参照,用加权Cohen κ比较两种方法,用ROC曲线计算EPIMix检测进展期病变的敏感度、特异度和AUC。
诊断标准与关键数值
- 以常规临床MRI为参照、按RANO 2.0标准,EPIMix检测进展期病变的敏感度R1为1.00(0.81-1.00)、R2为0.90(0.68-0.99),特异度R1和R2均为0.97(0.86-1.00),AUC R1为0.99、R2为0.94;肿瘤分类评估EPIMix与常规临床MRI的加权κ值R1为0.96、R2为0.89;DeLong检验比较两读者AUC得P=0.20。
临床应用与阅片要点
- 本研究中EPIMix与常规临床MRI的肿瘤分类一致性接近完美(κ=0.96和0.89),检测进展期病变的敏感度R1为1.00、R2为0.90,特异度均为0.97,AUC R1为0.99、R2为0.94。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: EPIMix is a fast brain MRI technique not previously investigated in patients with grade 3 and 4 gliomas. This pilot study aimed to investigate the diagnostic performance of EPIMix in the radiological treatment evaluation of adult patients with grade 3 and 4 gliomas compared with routine clinical MRI (rcMRI).
MATERIALS AND METHODS: Patients with grade 3 and 4 gliomas investigated with rcMRI and EPIMix were retrospectively included in the study. Three readers (R1-R3) participated in the radiological assessment applying the Response Assessment for Neuro-Oncology (RANO 2.0) criteria, of whom two (R1 and R2) independently evaluated EPIMix and later rcMRI by measuring contrast-enhancing and non-contrast-enhancing tumor regions at each follow-up. For cases with discrepant evaluations, an unblinded side-by-side (EPIMix and rcMRI) reading was performed together with a third reader (R3). Comparisons between methods (EPIMix versus rcMRI) were performed using the weighted Cohen κ. The sensitivity and specificity to progressive disease (PD) on a follow-up scan were calculated for EPIMix compared with rcMRI with receiver operating characteristic curves (ROC) to assess the area under the curve (AUC).
RESULTS: Of 35 patients (mean age, 53 years; 31% women), a total of 93 MRIs encompassing 58 follow-up investigations showed PD at a blinded reading in 33% of EPIMix (19/58, R1-2), while in 31% (18/58 exams, R1), and 34% (20/58 exams, R2) of rcMRI. An almost perfect agreement for tumor category assessment was found between EPIMix and rcMRI (EPIMixR1 versus rcMRIR1 κ = 0.96; EPIMixR2 versus rcMRIR2 κ = 0.89). The sensitivity for EPIMix to detect PD was 1.00 (0.81-1.00) for R1 and 0.90 (0.68-0.99) for R2, while the specificity was 0.97 (0.86-1.00) for R1 and R2. The AUC for PD was 0.99 for R1 (EPIMixR1 versus rcMRIR1) and 0.94 for R2 (EPIMixR2 versus rcMRIR2). The P value of the DeLong test AUCR1 versus AUCR2 was P = .20 (R1-R2).
CONCLUSIONS: In this pilot study, EPIMix was used as a fast MRI alternative for treatment evaluation of patients with glioma grades 3 and 4, with high but slightly lower diagnostic performance than rcMRI.
引用
- De Luca F, Suneson A, Kits A, et al. Diagnostic Performance of Fast Brain MRI Compared with Routine Clinical MRI in Patients with Glioma Grades 3 and 4: A Pilot Study. AJNR Am J Neuroradiol. 2025. PMID: 39477545. doi:10.3174/ajnr.A8558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。